Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP raised its holdings in Biohaven Ltd. (NYSE:BHVN) by 190.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 121,554 shares of the company’s stock after purchasing an additional 79,640 shares during the quarter. Quantinno Capital Management LP owned 0.08% of Biohaven worth $1,028,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC raised its stake in shares of Biohaven by 83.0% during the 4th quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock valued at $116,140,000 after buying an additional 4,666,666 shares during the last quarter. Infinitum Asset Management LLC boosted its stake in shares of Biohaven by 267.6% in the fourth quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock worth $70,562,000 after buying an additional 4,550,000 shares during the last quarter. Stifel Financial Corp boosted its stake in shares of Biohaven by 50.3% in the fourth quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock worth $112,221,000 after buying an additional 3,328,506 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in Biohaven by 3,829.9% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 1,606,777 shares of the company’s stock worth $18,141,000 after acquiring an additional 1,565,891 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Biohaven by 52.9% during the fourth quarter. Vanguard Group Inc. now owns 4,395,946 shares of the company’s stock worth $49,630,000 after acquiring an additional 1,520,756 shares during the period. 88.78% of the stock is owned by institutional investors and hedge funds.

Biohaven Stock Performance

NYSE BHVN opened at $14.66 on Friday. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -3.16 and a beta of 1.26. Biohaven Ltd. has a twelve month low of $7.48 and a twelve month high of $18.57. The company has a current ratio of 4.73, a quick ratio of 7.41 and a debt-to-equity ratio of 21.23. The stock has a 50-day moving average of $14.32 and a 200 day moving average of $11.69.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Sell-side analysts anticipate that Biohaven Ltd. will post -3.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BHVN. Bank of America reissued an “underperform” rating and issued a $11.00 price target (down from $12.00) on shares of Biohaven in a report on Monday, June 29th. Needham & Company LLC set a $11.00 price objective on shares of Biohaven in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biohaven in a report on Tuesday, June 2nd. HC Wainwright reaffirmed a “neutral” rating and set a $10.00 target price on shares of Biohaven in a report on Tuesday, May 26th. Finally, Morgan Stanley boosted their target price on shares of Biohaven from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Biohaven has an average rating of “Moderate Buy” and a consensus price target of $21.75.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.